Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

Executive Summary

The reform 'blueprint' might actually live up to its hype.

You may also be interested in...



Rebate Reform: Big Changes Are Looming For The US Drug Market

Changing US drug rebating policy is like throwing an activated grenade into the middle of the American drug distribution system. Yet, increasingly it seems the US drug market is poised for a big shake up when it comes to the way pharmaceuticals manufacturers price their drugs, negotiate market access with payers, and pay back-end discounts to offset the cost of their products. 

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Boasting of 14 current or near-term blockbusters and success staving off Remicade biosimilars, Johnson & Johnson says its growth derives 100% from sales volume, not price increases. All the same, it continues call for slow pricing reform.

Lilly Looks To Spin Off Animal Health, Focus Cash On Pharma Growth

Lilly confirmed that it will separate its Elanco animal health business from the rest of the company via an IPO, allowing Lilly to focus its resources on pharma growth driven by internal and acquired drugs.

Related Content

Topics

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel